$3.84
+0.05
(+1.32%)▲
1.56%
Downside
Day's Volatility :5.5%
Upside
4.0%
11.08%
Downside
52 Weeks Volatility :69.78%
Upside
66.02%
Period | Hookipa Pharma Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -17.77% | -2.1% | 0.0% |
6 Months | -58.72% | 4.9% | 0.0% |
1 Year | -16.67% | 16.0% | 0.0% |
3 Years | -92.75% | 9.2% | -26.4% |
Market Capitalization | 38.2M |
Book Value | $7.14 |
Earnings Per Share (EPS) | -4.12 |
Wall Street Target Price | 44.8 |
Profit Margin | -93.16% |
Operating Margin TTM | -1736.74% |
Return On Assets TTM | -20.1% |
Return On Equity TTM | -48.99% |
Revenue TTM | 52.2M |
Revenue Per Share TTM | 4.4 |
Quarterly Revenue Growth YOY | -51.800000000000004% |
Gross Profit TTM | -53.0M |
EBITDA | -47.7M |
Diluted Eps TTM | -4.12 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.26 |
EPS Estimate Next Year | -5.43 |
EPS Estimate Current Quarter | -1.25 |
EPS Estimate Next Quarter | -1.41 |
What analysts predicted
Upside of 1066.67%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 7.6M | - |
Net Income | -16.2M | ↑ 27.62% |
Net Profit Margin | -212.83% | - |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 11.9M | ↑ 56.53% |
Net Income | -34.1M | ↑ 110.3% |
Net Profit Margin | -285.94% | ↓ 73.11% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 19.6M | ↑ 63.99% |
Net Income | -33.8M | ↓ 1.01% |
Net Profit Margin | -172.59% | ↑ 113.35% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 18.4M | ↓ 5.8% |
Net Income | -75.7M | ↑ 123.86% |
Net Profit Margin | -410.16% | ↓ 237.57% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 14.2M | ↓ 22.76% |
Net Income | -65.1M | ↓ 13.9% |
Net Profit Margin | -457.19% | ↓ 47.03% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 20.1M | ↑ 41.27% |
Net Income | -81.6M | ↑ 25.23% |
Net Profit Margin | -405.29% | ↑ 51.9% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.2M | ↓ 59.43% |
Net Income | -19.9M | ↑ 58.57% |
Net Profit Margin | -626.1% | ↓ 465.91% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.7M | ↓ 15.65% |
Net Income | -18.0M | ↓ 9.4% |
Net Profit Margin | -672.49% | ↓ 46.39% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 6.9M | ↑ 156.33% |
Net Income | -19.1M | ↑ 5.83% |
Net Profit Margin | -277.65% | ↑ 394.84% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 7.4M | ↑ 7.86% |
Net Income | -24.8M | ↑ 30.17% |
Net Profit Margin | -335.06% | ↓ 57.41% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 36.6M | ↑ 394.11% |
Net Income | 14.4M | ↓ 157.95% |
Net Profit Margin | 39.3% | ↑ 374.36% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 1.3M | ↓ 96.48% |
Net Income | -19.1M | ↓ 232.76% |
Net Profit Margin | -1.5K% | ↓ 1519.53% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 68.3M | ↓ 7.43% |
Total Liabilities | 23.9M | ↓ 79.51% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 143.7M | ↑ 110.61% |
Total Liabilities | 25.8M | ↑ 8.36% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 187.8M | ↑ 30.66% |
Total Liabilities | 31.7M | ↑ 22.63% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 126.0M | ↓ 32.89% |
Total Liabilities | 36.5M | ↑ 15.02% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 170.5M | ↑ 35.23% |
Total Liabilities | 67.9M | ↑ 86.37% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 161.3M | ↓ 5.35% |
Total Liabilities | 71.5M | ↑ 5.22% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 163.1M | ↓ 4.32% |
Total Liabilities | 79.6M | ↑ 17.18% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 191.1M | ↑ 17.18% |
Total Liabilities | 78.8M | ↓ 1.04% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 164.0M | ↓ 14.18% |
Total Liabilities | 69.0M | ↓ 12.47% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 161.3M | ↓ 1.63% |
Total Liabilities | 71.5M | ↑ 3.66% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 145.9M | ↓ 9.59% |
Total Liabilities | 41.3M | ↓ 42.15% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 125.0M | ↓ 14.28% |
Total Liabilities | 39.0M | ↓ 5.72% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -15.0M | ↑ 25.9% |
Investing Cash Flow | -2.2M | ↑ 65.77% |
Financing Cash Flow | 6.9M | ↓ 88.33% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -41.7M | ↑ 178.24% |
Investing Cash Flow | -2.0M | ↓ 7.02% |
Financing Cash Flow | 109.8M | ↑ 1496.84% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -39.3M | ↓ 5.73% |
Investing Cash Flow | -2.4M | ↑ 18.61% |
Financing Cash Flow | 73.4M | ↓ 33.1% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -66.0M | ↑ 67.81% |
Investing Cash Flow | -12.6M | ↑ 430.62% |
Financing Cash Flow | -235.0K | ↓ 100.32% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -20.0M | ↓ 69.71% |
Investing Cash Flow | -5.0M | ↓ 60.12% |
Financing Cash Flow | 72.3M | ↓ 30853.62% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.8M | ↓ 121.68% |
Investing Cash Flow | -274.0K | ↓ 54.26% |
Financing Cash Flow | -735.0K | ↑ 275.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -19.3M | ↑ 578.83% |
Investing Cash Flow | -445.0K | ↑ 62.41% |
Financing Cash Flow | 45.8M | ↓ 6333.33% |
Sell
Neutral
Buy
Hookipa Pharma Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Hookipa Pharma Inc. | -6.34% | -58.72% | -16.67% | -92.75% | -95.13% |
Vertex Pharmaceuticals Incorporated | 3.87% | 17.46% | 25.23% | 149.18% | 136.25% |
Alnylam Pharmaceuticals, Inc. | 1.63% | 79.81% | 63.67% | 58.45% | 198.57% |
Regeneron Pharmaceuticals, Inc. | -16.85% | -11.85% | 3.27% | 29.37% | 171.22% |
Biontech Se | -6.94% | 20.23% | 16.39% | -62.26% | 487.66% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Hookipa Pharma Inc. | NA | NA | NA | -2.26 | -0.49 | -0.2 | NA | 7.14 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.21 | 0.16 | -0.03 | 0.13 | NA | 57.26 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.39 | -15.01 | 0.02 | NA | -0.02 |
Regeneron Pharmaceuticals, Inc. | 20.75 | 20.75 | 1.18 | 44.77 | 0.17 | 0.08 | NA | 242.47 |
Biontech Se | 160.8 | NA | 0.04 | -2.76 | -0.03 | -0.02 | NA | 80.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Hookipa Pharma Inc. | Buy | $38.2M | -95.13% | NA | -93.16% |
Vertex Pharmaceuticals Incorporated | Buy | $122.9B | 136.25% | 32.84 | -4.74% |
Alnylam Pharmaceuticals, Inc. | Buy | $36.5B | 198.57% | NA | -3.11% |
Regeneron Pharmaceuticals, Inc. | Buy | $101.7B | 171.22% | 20.75 | 32.04% |
Biontech Se | Buy | $27.1B | 487.66% | 160.8 | -18.75% |
Insights on Hookipa Pharma Inc.
Revenue is down for the last 2 quarters, 36.59M → 1.29M (in $), with an average decrease of 96.5% per quarter
Netprofit is down for the last 2 quarters, 14.38M → -19.09M (in $), with an average decrease of 232.8% per quarter
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 63.7% return, outperforming this stock by 80.4%
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 58.4% return, outperforming this stock by 151.2%
Baker Bros Advisors LP
EcoR1 Capital, LLC
Artal Group S A
Knoll Capital Management LP
FMR Inc
Vanguard Group Inc
hookipa pharma inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. with this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. our arenavirus technologies, vaxwave®, a replication-deficient viral vector, and therat®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and cd8+ t cells. both, vaxwave® and therat®, can be administered repeatedly while maintaining their efficacy. therat® induced cd8+ t cell responses to tumor antigens reach frequencies and potencies matching or exceeding those observed after adoptive t cell therapy. hookipa’s “off-the shelf” viral vectors are administered systemically. they target dendritic cells in vivo and activate the immune system. in immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic). at hookipa we have successfully completed a phase 1 trial of a
Organization | Hookipa Pharma Inc. |
Employees | 151 |
CEO | Dr. Malte Peters M.D. |
Industry | Pharmaceuticals: Major |
Victoryshares International
$3.84
+1.32%
Clearbridge Focus Value Esg Etf
$3.84
+1.32%
Cabana Target Drawdwn 10 Etf
$3.84
+1.32%
Spdr Nyse Technology Etf
$3.84
+1.32%
Global Ship Lease Inc-cl A
$3.84
+1.32%
Standard Motor Products Inc
$3.84
+1.32%
Cp High Yield Trend Etf
$3.84
+1.32%
Gain Therapeutics Inc
$3.84
+1.32%
Olaplex Holdings, Inc.
$3.84
+1.32%